Human Pharmaceutical and Medicinal Product Manufacturing

ANZSIC class 1841 · 21 mergers

Since February 2026, the ACCC has reviewed 21 acquisitions in the Human Pharmaceutical and Medicinal Product Manufacturing industry (ANZSIC class 1841): 13 notified mergers and 8 waiver applications. Outcomes so far: 18 approved, 2 not approved and 1 still under assessment. The most frequent acquirers are Eli Lilly (6) and Gilead (2). Completed Phase 1 reviews took a median of 17 business days, and waivers a median of 18 business days. The most recent, Sun Pharma - Organon, was lodged on 22 October 2026.

Total reviews

21

Phase 2 reviews

0

Waivers

8

Under assessment

1